Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The black-eyed pea (Vigna unguiculata) is a widely cultivated legume, particularly in semi-arid regions, known for its high protein content and nutritional value. It is consumed globally as an edible seed and is a source of various metabolites, including saponins, alkaloids, phenolic acids, iridoids, and terpenes. Components derived from black-eyed peas, such as the Bowman-Birk protease inhibitor (BTCI), have been investigated for potential therapeutic applications, including anti-cancer effects and protease inhibition. The plant itself is also studied for its agricultural properties, such as its role as a host for pests and pathogens, and its response to different growing conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Black-eyed pea.